Compare Boston Scientific Corporation (BSX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs NIO Inc. — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while NIO Inc. trades at $5.02 (market cap $12.99B). The key difference: Boston Scientific Corporation is far larger — about 5.1× NIO Inc.'s market cap, and NIO Inc. is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | NIO | |
|---|---|---|
Market Cap | $66.37B | $12.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $7.89 |
52-Week Low | $42.63 | $4.11 |
Enterprise Value | $75.94B | $12.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
NIO trades at $4.93, up 3.14% today, but remains in a bearish technical trend with negative cash flows and persistent losses despite revenue growth to $87.49 billion in 2025. The company beat EPS estimates for three consecutive quarters, and June 2026 deliveries surged 62.9% year-over-year, indicating strong operational momentum. However, net income margin improved to -17.8% in 2025 but remains deep in negative territory, with a high debt load and substantial cash burn from operations.
Outlook is mixed: bullish delivery growth and analyst upgrades (Goldman Sachs to Buy, target $7) contrast with profitability risks and competitive EV market pressures. Investment appeal hinges on margin improvement and sustainable cash flow generation, while key risks include execution challenges, macroeconomic headwinds, and reliance on financing amid negative equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
